Patient characteristics
. | . | . | . | Related . | . | |
|---|---|---|---|---|---|---|
. | All patients, n = 105 . | CB, n = 15 . | MUD, n = 38 . | Matched, n = 32 . | Mismatched, n = 20 . | |
| Median age, y (range) | 25 (4-56) | 12 (5-51) | 24 (6-48) | 29 (5-56) | 24 (4-45) | |
| Disease stage at BMT | ||||||
| Active | 33 (31%) | 4 | 12 | 8 | 9 | |
| Complete remission | 72 (69%) | 11 | 26 | 24 | 11 | |
| Preparative regimen | ||||||
| CyTBI | 14 (13%) | 0 | 3 | 10 | 1 | |
| CyTBI Thio | 53 (51%) | 1 | 33 | 1 | 18 | |
| CyTBI VP16 | 19 (18%) | 0 | 1 | 17 | 1 | |
| FM TBI | 16 (15%) | 11 | 1 | 4 | 0 | |
| Fludarabine TBI | 3 (3%) | 3 | 0 | 0 | 0 | |
| GVHD prophylaxis | ||||||
| Tacrolimus and MTX | 60 (57%) | 14 | 20 | 20 | 6 | |
| Cyclosporine based | ||||||
| Cyclosporine | 1 (1%) | 0 | 0 | 0 | 1 | |
| Cyclosporine and MTX | 9 (9%) | 0 | 0 | 9 | 0 | |
| Intense* | 35 (33%) | 1 | 18 | 3 | 13 | |
| ATG with preparative regimen | 28 (27%) | 1 | 15 | 1 | 11 | |
. | . | . | . | Related . | . | |
|---|---|---|---|---|---|---|
. | All patients, n = 105 . | CB, n = 15 . | MUD, n = 38 . | Matched, n = 32 . | Mismatched, n = 20 . | |
| Median age, y (range) | 25 (4-56) | 12 (5-51) | 24 (6-48) | 29 (5-56) | 24 (4-45) | |
| Disease stage at BMT | ||||||
| Active | 33 (31%) | 4 | 12 | 8 | 9 | |
| Complete remission | 72 (69%) | 11 | 26 | 24 | 11 | |
| Preparative regimen | ||||||
| CyTBI | 14 (13%) | 0 | 3 | 10 | 1 | |
| CyTBI Thio | 53 (51%) | 1 | 33 | 1 | 18 | |
| CyTBI VP16 | 19 (18%) | 0 | 1 | 17 | 1 | |
| FM TBI | 16 (15%) | 11 | 1 | 4 | 0 | |
| Fludarabine TBI | 3 (3%) | 3 | 0 | 0 | 0 | |
| GVHD prophylaxis | ||||||
| Tacrolimus and MTX | 60 (57%) | 14 | 20 | 20 | 6 | |
| Cyclosporine based | ||||||
| Cyclosporine | 1 (1%) | 0 | 0 | 0 | 1 | |
| Cyclosporine and MTX | 9 (9%) | 0 | 0 | 9 | 0 | |
| Intense* | 35 (33%) | 1 | 18 | 3 | 13 | |
| ATG with preparative regimen | 28 (27%) | 1 | 15 | 1 | 11 | |
Cy TBI indicates cyclophosphamide and total body irradiation; Thio, thiotepa; ATG, anti-thymocyte globulin; VP16, etoposide; FM, fludarabine and melphalan; GVHD, graft-versus-host disease; MTX, methotrexate; CSA, cyclosporine; CB, cord blood transplant; MUD, matched unrelated donor.
Intense includes patients who took other GVHD prophylaxis besides standard regimen of CSA and MTX or FK506 and MTX include (xomazyme, n = 13; T-cell purged and methylprednisolone, n = 4; steroids, n = 2; ATG in the preparative regimen, n = 28).